SCHEMBL1481820

SCHEMBL1481820

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc2cc(O)ccc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
MAPT P10636 4/20 0.37
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
DPP4 P27487 2/20 0.33
DPP8 Q6V1X1 2/20 0.33
ALPL P05186 2/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KDM4E B2RXH2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HSP90AA1 P07900 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481818 1.00 LMNA (0.37) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1482170 0.91 MAPT (0.42) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1482165 0.91 MAPT (0.42) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1480644 0.88 MEN1 (0.45) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1480642 0.88 MEN1 (0.45) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1481166 0.88 RELA (0.38) LMNAMAPTMEN1KMT2AACHE
SCHEMBL1481164 0.88 RELA (0.38) LMNAMAPTMEN1KMT2AACHE
SCHEMBL1481420 0.85 LMNA (0.35) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1481423 0.85 LMNA (0.35) LMNAMAPTPTGS1PTGS2MEN1
SCHEMBL1484093 0.84 MEN1 (0.41) LMNAMAPTPTGS1PTGS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ LMNA 4711/4885MAPT 3558/4885PTGS1 777/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ LMNA 4711/4885MAPT 3558/4885PTGS1 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.